REGENXBIO Inc. Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss
REGENXBIO Inc. (RGNX) had Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss of $23.00 thousand as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Debt and Equity Securities › Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss
us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss · last filed 2026-08-06
- 2026-06-30: Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss $23.00K.
- 2026-03-31: Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss $49.00K.
- 2025-12-31: Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss $17.00K.
- 2025-09-30: Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss $16.00K.
| Period end | Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss | Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss as first filed |
|---|---|---|
| 2026-06-30 | $23.00K 10-Q · filed 2026-08-06 | |
| 2026-03-31 | $49.00K 10-Q · filed 2026-05-14 | |
| 2025-12-31 | $17.00K 10-Q · filed 2026-08-06 | |
| 2025-09-30 | $16.00K 10-Q · filed 2025-11-06 | |
| 2025-06-30 | $56.00K 10-Q · filed 2025-08-07 | |
| 2025-03-31 | $36.00K 10-Q · filed 2025-05-12 | |
| 2024-12-31 | $126.00K 10-K · filed 2026-03-05 | |
| 2024-09-30 | $321.00K 10-Q · filed 2024-11-06 | |
| 2024-06-30 | $1.42M 10-Q · filed 2024-08-01 | |
| 2024-03-31 | $2.41M 10-Q · filed 2024-05-08 | |
| 2023-12-31 | $3.72M 10-K · filed 2025-03-13 | |
| 2023-09-30 | $6.55M 10-Q · filed 2023-11-08 | |
| 2023-06-30 | $9.24M 10-Q · filed 2023-08-02 | |
| 2023-03-31 | $10.77M 10-Q · filed 2023-05-03 | |
| 2022-12-31 | $14.54M 10-K · filed 2024-02-27 | |
| 2022-09-30 | $17.40M 10-Q · filed 2022-11-03 | |
| 2022-06-30 | $13.93M 10-Q · filed 2022-08-03 | |
| 2022-03-31 | $11.10M 10-Q · filed 2022-05-04 | |
| 2021-12-31 | $1.77M 10-K · filed 2023-02-28 | |
| 2021-09-30 | $476.00K 10-Q · filed 2021-11-02 | |
| 2021-06-30 | $543.00K 10-Q · filed 2021-08-09 | |
| 2021-03-31 | $755.00K 10-Q · filed 2021-05-05 | |
| 2020-12-31 | $55.00K 10-K · filed 2022-03-01 | |
| 2020-09-30 | $11.00K 10-Q · filed 2020-11-04 | |
| 2020-06-30 | $43.00K 10-Q · filed 2020-08-06 | |
| 2020-03-31 | $730.00K 10-Q · filed 2020-05-07 | |
| 2019-12-31 | $34.00K 10-K · filed 2021-03-01 | |
| 2019-09-30 | $34.00K 10-Q · filed 2020-11-04 | $24.00K 10-Q · filed 2019-11-05 |
| 2019-06-30 | $34.00K 10-Q · filed 2020-08-06 | $3.00K 10-Q · filed 2019-08-07 |
| 2019-03-31 | $34.00K 10-Q · filed 2020-05-07 | $48.00K 10-Q · filed 2019-05-07 |
| 2018-12-31 | $414.00K 10-K · filed 2020-02-26 | |
| 2018-09-30 | $444.00K 10-Q · filed 2018-11-07 | |
| 2018-06-30 | $339.00K 10-Q · filed 2018-08-08 | |
| 2017-12-31 | $282.00K 10-K · filed 2019-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B |